Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:KOD NASDAQ:NTLA NASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.72+0.2%$4.19$2.93▼$7.55$590.87M1.461.43 million shs1.92 million shsKODKodiak Sciences$36.63+1.4%$38.60$3.51▼$47.84$2.26B2.21659,038 shs610,757 shsNTLAIntellia Therapeutics$15.75+0.5%$13.82$7.95▼$28.25$2.19B1.926.27 million shs5.10 million shsPHVSPharvaris$33.00+0.6%$30.13$16.72▼$34.41$2.15B-2.35292,872 shs304,133 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%+12.59%+13.96%+19.47%+44.46%KODKodiak Sciences0.00%+6.11%-0.25%+62.50%+898.34%NTLAIntellia Therapeutics0.00%+29.40%+24.37%+19.53%+70.33%PHVSPharvaris0.00%+6.77%+10.51%+27.63%+82.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.72+0.2%$4.19$2.93▼$7.55$590.87M1.461.43 million shs1.92 million shsKODKodiak Sciences$36.63+1.4%$38.60$3.51▼$47.84$2.26B2.21659,038 shs610,757 shsNTLAIntellia Therapeutics$15.75+0.5%$13.82$7.95▼$28.25$2.19B1.926.27 million shs5.10 million shsPHVSPharvaris$33.00+0.6%$30.13$16.72▼$34.41$2.15B-2.35292,872 shs304,133 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%+12.59%+13.96%+19.47%+44.46%KODKodiak Sciences0.00%+6.11%-0.25%+62.50%+898.34%NTLAIntellia Therapeutics0.00%+29.40%+24.37%+19.53%+70.33%PHVSPharvaris0.00%+6.77%+10.51%+27.63%+82.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.5078.68% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1415.34% UpsideNTLAIntellia Therapeutics 2.35Hold$20.4630.33% UpsidePHVSPharvaris 2.69Moderate Buy$49.1848.97% UpsideCurrent Analyst Ratings BreakdownLatest AQST, KOD, NTLA, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026PHVSPharvaris HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/16/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$49.006/15/2026NTLAIntellia Therapeutics New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.006/15/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/15/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/15/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.006/15/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$30.005/13/2026NTLAIntellia Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$13.00 ➝ $17.005/13/2026PHVSPharvaris UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.005/13/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/13/2026PHVSPharvaris Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$75.00 ➝ $74.00(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M13.40N/AN/A($0.28) per share-16.99KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ANTLAIntellia Therapeutics$67.67M32.41N/AN/A$5.80 per share2.71PHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)PHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%8/11/2026 (Estimated)Latest AQST, KOD, NTLA, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/A3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.103.85KODKodiak SciencesN/A3.543.54NTLAIntellia TherapeuticsN/A6.106.10PHVSPharvarisN/A11.2411.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%KODKodiak Sciences89.06%NTLAIntellia Therapeutics88.77%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%KODKodiak Sciences45.90%NTLAIntellia Therapeutics3.50%PHVSPharvarisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160125.45 million116.91 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableNTLAIntellia Therapeutics600139.72 million134.83 millionOptionablePHVSPharvaris3065.41 millionN/ANot OptionableAQST, KOD, NTLA, and PHVS HeadlinesRecent News About These CompaniesPharvaris N.V. (NASDAQ:PHVS) Given Average Rating of "Moderate Buy" by AnalystsJune 21 at 4:33 AM | americanbankingnews.comInsider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,291 Shares of StockJune 18, 2026 | insidertrades.comCommodore Capital LP Sells 529,031 Shares of Pharvaris N.V. $PHVSJune 18, 2026 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)June 17, 2026 | theglobeandmail.comData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026June 15, 2026 | finance.yahoo.comPharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026 - SlideshowJune 12, 2026 | seekingalpha.comPharvaris Announces Annual General Meeting of ShareholdersJune 11, 2026 | globenewswire.comPharvaris (NASDAQ:PHVS) Insider Sells $82,422.90 in StockJune 9, 2026 | insidertrades.comPharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy Conference - SlideshowMay 30, 2026 | seekingalpha.comPharvaris to Present Clinical Data at the EAACI Annual Congress 2026May 29, 2026 | globenewswire.comPharvaris (NASDAQ:PHVS) Insider Sells $55,967.40 in StockMay 27, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) Director Elisabeth Bjork Sells 10,000 SharesMay 23, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 SharesMay 21, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 10,000 SharesMay 20, 2026 | insidertrades.comPharvaris Equity Raise Supports Late Stage HAE Push And Valuation CaseMay 14, 2026 | finance.yahoo.comPharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comPharvaris Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comPharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 11, 2026 | finance.yahoo.comPharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 11, 2026 | globenewswire.comPharvaris N.V. Prices Underwritten Offering of 3,874,664 Ordinary Shares at $29.68 Per ShareMay 8, 2026 | quiverquant.comQPharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary SharesMay 8, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAQST, KOD, NTLA, and PHVS Company DescriptionsAquestive Therapeutics NASDAQ:AQST$4.72 +0.01 (+0.21%) Closing price 04:00 PM EasternExtended Trading$4.77 +0.05 (+1.04%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Kodiak Sciences NASDAQ:KOD$36.63 +0.49 (+1.36%) Closing price 04:00 PM EasternExtended Trading$36.50 -0.13 (-0.35%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Intellia Therapeutics NASDAQ:NTLA$15.75 +0.08 (+0.51%) Closing price 04:00 PM EasternExtended Trading$15.67 -0.08 (-0.50%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Pharvaris NASDAQ:PHVS$33.00 +0.20 (+0.61%) Closing price 04:00 PM EasternExtended Trading$33.00 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
